RÉSUMÉ
The inflammatory response is driven by signals that recruit and elicit immune cells to areas of tissue damage or infection. The concept of a mononuclear phagocyte system postulates that monocytes circulating in the bloodstream are recruited to inflamed tissues where they give rise to macrophages. A recent publication demonstrated that the large increase in the macrophages observed during infection was the result of the multiplication of these cells rather than the recruitment of blood monocytes. We demonstrated previously that B-1 cells undergo differentiation to acquire a mononuclear phagocyte phenotype in vitro (B-1CDP), and we propose that B-1 cells could be an alternative origin for peritoneal macrophages. A number of recent studies that describe the phagocytic and microbicidal activity of B-1 cells in vitro and in vivo support this hypothesis. Based on these findings, we further investigated the differentiation of B-1 cells into phagocytes in vivo in response to LPS-induced inflammation. Therefore, we investigated the role of B-1 cells in the composition of the peritoneal macrophage population after LPS stimulation using osteopetrotic mice, BALB/Xid mice and the depletion of monocytes/macrophages by clodronate treatment. We show that peritoneal macrophages appear in op/op((-/-)) mice after LPS stimulation and exhibit the same Ig gene rearrangement (VH11) that is often found in B-1 cells. These results strongly suggest that op/op((-/-)) peritoneal "macrophages" are B-1CDP. Similarly, the LPS-induced increase in the macrophage population was observed even following monocyte/macrophage depletion by clodronate. After monocyte/macrophage depletion by clodronate, LPS-elicited macrophages were observed in BALB/Xid mice only following the transfer of B-1 cells. Based on these data, we confirmed that B-1 cell differentiation into phagocytes also occurs in vivo. In conclusion, the results strongly suggest that B-1 cell derived phagocytes are a component of the LPS-elicited peritoneal macrophage population.
Sujet(s)
Sous-populations de lymphocytes B/immunologie , Lipopolysaccharides/immunologie , Macrophages péritonéaux/immunologie , Phagocytes/immunologie , Animaux , Sous-populations de lymphocytes B/cytologie , Différenciation cellulaire , Cellules cultivées , Gènes d'immunoglobuline , Inflammation/immunologie , Macrophages péritonéaux/cytologie , Macrophages péritonéaux/métabolisme , Souris , Souris de lignée BALB C , Souris de lignée C57BL , Phagocytes/cytologie , Phagocytes/métabolismeRÉSUMÉ
BACKGROUND: B-cell chronic lymphocytic leukemia (B-CLL) is a remarkably heterogeneous disorder. Some patients have an indolent disease whereas others undergo a more agressive presentation needing treatment. New therapeutics approaches are necessary for the treatment of B-CLL. Bortezomib (Btz), is a proteasome inhibitor, currently undergoing clinical trials whose function, at least in part, by stabilizing the IkappaBalpha protein and inhibiting NFkappaB activation. OBJECTIVE: The objective of this work was to study the effects of Btz on isolated human B-CLL cells, in vitro, and to correlate the differential rates of apoptosis induction with biological variables. MATERIAL AND METHODS: 31 B-CLL samples, from patients in stage A of Binet were used for this study, and the apoptotic effect of Btz on these cells was measured. RESULTS: Our data show that Btz treatment of B-CLL cells induces apoptosis in a time and dose-dependent manner. The apoptosis induction is mediated in part by inhibition of NFkappaB and is dependent on caspases activation. Interesting, in IgVH mutated cells, Btz have statistically significant differences in their in vitro activity on B-CLL cells according to their BCL-6 mutational status. CONCLUSIONS: Btz is a promising pharmacologic agent for the treatment of B-CLL, but its efficacy seems to be related to IgVH and BCL-6 mutational status, therefore, it could be interesting to further investigate the mechanisms involved in the different behavior of the cells in response to apoptosis induction by this drug.
Sujet(s)
Antinéoplasiques/pharmacologie , Apoptose/effets des médicaments et des substances chimiques , Acides boroniques/pharmacologie , Réarrangement des gènes des chaines lourdes des lymphocytes B , Leucémie chronique lymphocytaire à cellules B/anatomopathologie , Protéines tumorales/antagonistes et inhibiteurs , Inhibiteurs de protéines kinases/pharmacologie , Protein-tyrosine kinases/antagonistes et inhibiteurs , Protéines proto-oncogènes c-bcl-6/génétique , Pyrazines/pharmacologie , Antigènes CD38/biosynthèse , Antigènes CD38/génétique , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Chlorométhyl cétones d'acides aminés/pharmacologie , Antinéoplasiques/administration et posologie , Acides boroniques/administration et posologie , Bortézomib , Inhibiteurs des caspases , Caspases/physiologie , Inhibiteurs de la cystéine protéinase/pharmacologie , Relation dose-effet des médicaments , Tests de criblage d'agents antitumoraux , Femelle , Gènes d'immunoglobuline , Humains , I-kappa B Kinase/antagonistes et inhibiteurs , Protéines I-kappa B/métabolisme , Chaines lourdes des immunoglobulines/génétique , Région variable d'immunoglobuline/génétique , Leucémie chronique lymphocytaire à cellules B/génétique , Mâle , Adulte d'âge moyen , Facteur de transcription NF-kappa B/antagonistes et inhibiteurs , Protéines tumorales/physiologie , Nitriles/pharmacologie , Phosphorylation/effets des médicaments et des substances chimiques , Inhibiteurs de protéines kinases/administration et posologie , Maturation post-traductionnelle des protéines/effets des médicaments et des substances chimiques , Protein-tyrosine kinases/physiologie , Pyrazines/administration et posologie , Sulfones/pharmacologie , Cellules cancéreuses en culture/effets des médicaments et des substances chimiques , Cellules cancéreuses en culture/métabolisme , ZAP-70 Protein-tyrosine kinase/biosynthèse , ZAP-70 Protein-tyrosine kinase/génétiqueRÉSUMÉ
A humanized monoclonal antibody (mAb) has been developed and its potential to protect from or cure a Venezuelan equine encephalomyelitis virus (VEEV) infection was evaluated. The VEEV-neutralizing, protective murine mAb 3B4C-4 was humanized using combinatorial antibody libraries and phage-display technology. Humanized VEEV-binding Fabs were evaluated for virus-neutralizing capacity, then selected Fabs were converted to whole immunoglobulin (Ig) G1, and stable cell lines were generated. The humanized mAb Hy4-26C, designated Hy4 IgG, had virus-neutralizing capacity similar to that of 3B4C-4. Passive antibody protection studies with purified Hy4 IgG were performed in adult Swiss Webster mice. As little as 100 ng Hy4 IgG protected 90 % of mice challenged with 100 intraperitoneal (i.p.) mean morbidity (MD(50)) doses of virulent VEEV (Trinidad donkey) 24 h after antibody transfer; also, 500 mug Hy4 IgG protected 80 % of mice inoculated with 100 intranasal MD(50) doses of VEEV. Moreover, 10 mug passive Hy4 IgG protected 70 % of mice from a VEEV challenge dose as great as 10(7) i.p. MD(50). Hy4 IgG also protected mice from challenge with another epizootic VEEV variety, 1C (P676). Importantly, therapeutic administration of the humanized mAb to mice already infected with VEEV cured 90 % of mice treated with Hy4 IgG within 1 h of VEEV inoculation and 75 % of mice treated 24 h after virus infection.
Sujet(s)
Anticorps monoclonaux/administration et posologie , Anticorps antiviraux/administration et posologie , Virus de l'encéphalite équine du Venezuela/immunologie , Encéphalomyélite équine du Vénézuéla/prévention et contrôle , Encéphalomyélite équine du Vénézuéla/thérapie , Animaux , Anticorps monoclonaux/génétique , Anticorps monoclonaux/usage thérapeutique , Anticorps antiviraux/génétique , Anticorps antiviraux/usage thérapeutique , Séquence nucléotidique , Clonage moléculaire , Virus de l'encéphalite équine du Venezuela/pathogénicité , Encéphalomyélite équine du Vénézuéla/immunologie , Gènes d'immunoglobuline , Humains , Immunisation passive , Immunoglobuline G/administration et posologie , Immunoglobuline G/génétique , Immunoglobuline G/usage thérapeutique , Souris , Données de séquences moléculaires , Tests de neutralisation , Oligodésoxyribonucléotides/génétiqueRÉSUMÉ
A leucemia linfóide crônica foi durante muito tempo entendida como uma doença relativamente homogênea causada pela acumulação de linfócitos B monoclonais, imuno-incompetentes e com graves distúrbios nos mecanismos normais de apoptose. Evidências recentes demonstram que as células leucêmicas LLC constituem-se em linfócitos B previamente expostos a antígenos, ou seja, provavelmente imunoðcompetentes. Além disso, ao contrário do que se acreditava, o aparato de apoptose destas células parece estar intacto. Pelo menos dois subgrupos distintos de LLC podem ser caracterizados por particularidades imunobiológicas, cursos clínicos e prognósticos distintos. A presença de mutações somáticas em genes da região variável de imunoglobulina define estes dois subtipos, onde o grupo não mutado apresenta melhor prognóstico, ao passo que o grupo com mutações indica cursa com pior prognóstico. A célula de origem da LLC, ou seja, a célula em que o evento leuceðmogênico inicial ocorre provavelmente é um progenitor linfóide, com boa parte da sua maquinaria transcipcinal comprometida com a linhagem B, mas com algumas características de linfócitos T anormalmente expressas. A progressão destas células para os linfócitos tipicamente LLC depende de estimulação antigênica. Tanto as formas não mutada como mutada expressam BCR, mas, aparentemente, as células com mutação são anérgicas. Células de LLC não mutada apresentam telômeros mais curtos que nos casos com mutação, indicando que os primeiros devem sofrer um número maior de divisões celulares e, portanto, uma maior probabilidade de adquirirem mutações. A expressão anômala de ZAP70, uma tirosina-quinase importante no processo de fosforilação de CD3 em linfócitos T, associa-se fortemente com o status não mutado e pode ser utilizado como um possível "surrogate" para a avaliação prognóstica. Alterações citogenéticas são freqüentes em LLC, mas provavelmente são fenômenos tardios da doença e a sua aquisição apresenta...
For decades, chronic lymphocytic leukemia (CLL) has been regarded as homogeneous entity caused by the accumulation of monoclonal and immunoincompetent B cells with dysfunctional apoptotic pathways. Recently, many of these certainties have been questioned by evidence that demonstrate that CLL cells have been previously challenged by antigens, and therefore are immunoðcompetent cells. Moreover, in proliferative compartments, like the mantle zone of lymphoid organs or pseudo-follicles in the bone marrow, defects in proliferation seems to be as important as apoptosis impairment in the pathogenesis of the disorder. Two distinct subgroups of CLL can be segregated based on immunoðbiologic characteristics, clinical course and outcomes. The two subgroups can be identified by the presence of somatic mutations in the variable region of the heavy chain gene. The unmutated group presents a better outcome and is probably composed of anergized B cells previously exposed to an antigen which frequently affects a common segment of the variable region. The mutated group courses with a poorer prognosis and commonly presents an abnormal expression of ZAP70, a typical T-cell tyrosine kinase. The cell which originates CLL is a very early lymphocyte that still bears some T-cell characteristics, such as CD5 and ZAP70 expressions, but with the transcriptional machinery committed to the B-lineage. The original genetic lesion in this CLL primary cell is unknown. Cytogenetic abnormalities are frequently seen in the circulating lymphocytes and are probably late events in the pathogenesis of CLL.
Sujet(s)
Humains , Analyse de mutations d'ADN , Gènes d'immunoglobuline , Leucémie chronique lymphocytaire à cellules B , Leucémie lymphoïdeRÉSUMÉ
In order to characterize immunoglobulin heavy-chain variable (IGHV) genes in Aotus nancymaae monkeys, different mRNAs encoded by five IGHV families in this non-human primate were molecularly analysed considering their paramount importance in antibody production in an immune response. This study reports gene products exhibiting 91% amino acid similarity with IGHV1, IGHV2, IGHV3, IGHV4 and IGHV7 human IGHV families. Our analyses suggest that the IGHV gene has several conserved characteristics in humans and A. nancymaae. Several amino acid residues that are highly conserved in all family members described in humans were also present in these families in A. nancymaae. Antibody diversity in these families has remained the same since divergence of both species. Our study continues to provide evidence supporting the use of A. nancymaae monkey as an animal model for studying antibody response.
Sujet(s)
Aotidae/génétique , Gènes d'immunoglobuline , Chaines lourdes des immunoglobulines/génétique , Région variable d'immunoglobuline/génétique , Séquence d'acides aminés , Animaux , Diversité des anticorps/génétique , Aotidae/immunologie , Clonage moléculaire , Humains , Données de séquences moléculaires , Famille multigénique , Phylogenèse , Réaction de polymérisation en chaîne , ARN messager/génétique , ARN messager/métabolisme , Similitude de séquences d'acides aminésRÉSUMÉ
It has been proposed that the defense and recognition functions of the immune system, especially those mediated by antibodies, require a great diversity of receptors. Nonetheless, functional and structural evidence has demonstrated the presence of restrictions, both in the use of the repertoire and in the recognition of antigens. Fifty-one functional genes have been described in the IghV locus; however, there is a variety of evidences indicating that only a small fraction of the immunoglobulin genes plays a central role in determining the fundamental properties of the antibody repertoire of the immune system. On the basis of this functional and structural information, we selected four IghV genes and characterized their polymorphism in a sample of Mexican individuals. We also analyzed the implications for the recognition mechanism of the substitutions found in the sequenced alleles. We found that diversification through allelism varies from segment to segment, both in the amount of alleles encountered and in the nature and distribution of mutations in the codifying zone, which might depend on its importance for the repertoire. Such functional characteristics may be useful in the interpretation of differential gene usage in certain physiological, ontological, and/or pathological conditions.
Sujet(s)
Gènes d'immunoglobuline , Chaines lourdes des immunoglobulines/génétique , Région variable d'immunoglobuline/génétique , Allèles , Séquence d'acides aminés , Substitution d'acide aminé/génétique , Séquence nucléotidique , Humains , Mexique , Données de séquences moléculaires , Mutation ponctuelle , Polymorphisme génétique , Alignement de séquencesRÉSUMÉ
The diversity in repertoires of antibodies (Abs) needed in response to the antigen challenge is produced by evolutionary and somatic processes. The mechanisms operating at a somatic level have been studied in great detail. In contrast, neither the mechanisms nor the strategies of diversification at an evolutionary level have yet been understood in similar detail. Particularly, the substitution patterns in alleles of immunoglobulin genes (Igs) have not been systematically studied. Furthermore, there is a scarcity of studies which link the analysis at a genetic level of the diversification of repertoires with the structural consequences at the protein level of the changes in DNA information. For the purpose of systematically characterizing the strategies of evolutionary diversification through sequence variation at alleles, in this work, we built a database for all the alleles of the IGHV locus in humans reported until now. Based on these data, we performed diverse analyses of substitution patterns and linked these results with studies at the protein level. We found that the sequence diversification in different alleles does not operate with equal intensity for all V genes. Our studies, both of the number of substitutions and of the type of amino acid change per sub-segment of the V-REGION evidenced differences in the selective pressure to which these regions are exposed. The implications of these results for understanding the evolutionary diversification strategies, as well as for the somatic generation of antibody repertoires are discussed.
Sujet(s)
Allèles , Substitution d'acide aminé/génétique , Gènes d'immunoglobuline , Région variable d'immunoglobuline/génétique , Séquence d'acides aminés , Diversité des anticorps , Séquence nucléotidique , Évolution moléculaire , Variation génétique , Humains , Modèles moléculaires , Données de séquences moléculaires , Polymorphisme génétique , Structure tertiaire des protéines , Sélection génétique , Similitude de séquences d'acides aminésRÉSUMÉ
A single-chain fragment variable (scFv) antibody library displayed on phage was constructed using spleen cells from mice immunized with human amyloid-beta peptide (Abeta42). This first anti-Abeta42 scFv immune antibody library was selected against human Abeta42. A number of positive clones were obtained, and sequences of VH and Vkappa genes were analyzed using ExPASy and BLAST computer tools. This analysis revealed that only two unique clones with identical VH and Vkappa complementarity determining region (CDR) (except HCDR2) and identical germline genes were selected, indicating that oligoclonal immune response was occurring in Abeta42-immunized mice. Abeta42-specific scFv antibodies selected from this first immune anti-Abeta42 phage antibody library may be an important tool for the development of therapeutic molecules for Alzheimer's disease (AD).
Sujet(s)
Peptides bêta-amyloïdes/immunologie , Bactériophage M13/immunologie , Épitopes/immunologie , Fragments d'immunoglobuline/isolement et purification , Région variable d'immunoglobuline/isolement et purification , Fragments peptidiques/immunologie , Banque de peptides , Animaux , Bactériophage M13/génétique , Test ELISA , Gènes d'immunoglobuline , Vecteurs génétiques , Fragments d'immunoglobuline/biosynthèse , Fragments d'immunoglobuline/génétique , Chaines lourdes des immunoglobulines/génétique , Région variable d'immunoglobuline/biosynthèse , Région variable d'immunoglobuline/génétique , Chaines légères kappa des immunoglobulines/génétique , Souris , Analyse de séquence d'ADNRÉSUMÉ
The production of reactive oxygen species (ROS) by polymorphonuclear leukocytes (PMN) can be induced by immune complexes and is an important component of phagocytosis in the killing of microorganisms, but can also be involved in inflammatory reactions when immune complexes are deposited in tissues. We have observed that fluid-phase IgG can inhibit the generation of ROS by rabbit PMN stimulated with precipitated immune complexes of IgG (ICIgG) in a dose-dependent manner, acting as a modulatory factor in the range of physiological IgG concentrations. This inhibitory effect is compatible with the known affinity (Kd) of monomeric IgG for the receptors involved (FcRII and FcRIII). The presence of complement components in the immune complexes results in a higher stimulation of ROS production. In this case, however, there is no inhibition by fluid-phase IgG. The effect of complement is strongly dependent on the presence of divalent cations (Ca2+ or Mg2+) in the medium, whereas the stimulation of ICIgG (without complement) does not depend on these cations. We have obtained some evidence indicating that iC3b should be the component involved in the effect of complement through interaction with the CR3 receptor. The absence of the inhibitory effect of fluid-phase IgG in ROS production when complement is present in the immune complex shows that complement may be important in vivo not only in the production of chemotactic factors for PMN, but also in the next phase of the process, i.e., the generation of ROS.
Sujet(s)
Animaux , Lapins , Complexe antigène-anticorps , Protéines du système du complément , Gènes d'immunoglobuline , Granulocytes neutrophiles , Espèces réactives de l'oxygène , Complexe antigène-anticorps , Protéines du système du complément , OvalbumineRÉSUMÉ
Leprosy presents as a clinical and immunological spectrum of disease. With the use of gene expression profiling, we observed that a distinction in gene expression correlates with and accurately classifies the clinical form of the disease. Genes belonging to the leukocyte immunoglobulin-like receptor (LIR) family were significantly up-regulated in lesions of lepromatous patients suffering from the disseminated form of the infection. In functional studies, LIR-7 suppressed innate host defense mechanisms by shifting monocyte production from interleukin-12 toward interleukin-10 and by blocking antimicrobial activity triggered by Toll-like receptors. Gene expression profiles may be useful in defining clinical forms of disease and providing insights into the regulation of immune responses to pathogens.
Sujet(s)
Humains , Analyse de regroupements , Cytokines/génétique , Cytokines/métabolisme , Numération de colonies microbiennes , Glycoprotéines membranaires/immunologie , Lèpre tuberculoïde/classification , Lèpre tuberculoïde/physiopathologie , Lèpre tuberculoïde/génétique , Lèpre tuberculoïde/immunologie , Lèpre lépromateuse/classification , Lèpre lépromateuse/physiopathologie , Lèpre lépromateuse/génétique , Lèpre lépromateuse/immunologie , Immunité cellulaire , Immunité innée , Macrophages alvéolaires/microbiologie , Mycobacterium tuberculosis/croissance et développement , Mycobacterium tuberculosis/immunologie , Analyse de profil d'expression de gènes , Réaction de polymérisation en chaîne , Récepteurs immunologiques/génétique , Récepteurs immunologiques/métabolisme , Récepteurs de surface cellulaire/immunologie , Régulation de l'expression des gènes , Algorithmes , Analyse en composantes principales , Séquençage par oligonucléotides en batterie , Gènes d'immunoglobuline , Régulation positiveRÉSUMÉ
The evolvability of vertebrate systems involves various mechanisms that eventually generate cooperative and nonlethal functional variation on which Darwinian selection can operate. It is a truism that to get vertebrate animals to develop a coherent machine they first had to inherit the right multicellular ontogeny. The ontogeny of a metazoan involves cell lineages that progressively deny their own capacity for increase and for totipotency in benefit of the collective interest of the individual. To achieve such cell altruism Darwinian dynamics rescinded its original unicellular mandate to reproduce. The distinction between heritability at the level of the cell lineage and at the level of the individual is crucial. However, its implications have seldom been explored in depth. While all out reproduction is the Darwinian measure of success among unicellular organisms, a high replication rate of cell lineages within the organism may be deleterious to the individual as a functional unit. If a harmoniously functioning unit is to evolve, mechanisms must have evolved whereby variants that increase their own replication rate by failing to accept their own somatic duties are controlled. For questions involving organelle origins, see Godelle and Reboud, 1995 and Hoekstra, 1990. In other words, modifiers of conflict that control cell lineages with conflicting genes and new mutant replication rates that deviate from their somatic duties had to evolve. Our thesis is that selection at the level of the (multicellular) individual must have opposed selection at the level of the cell lineage. The metazoan embryo is not immune to this conflict especially with the evolution of set-aside cells and other modes of self-policing modifiers (Blackstone and Ellison, 1998; Ransick et al., 1996. In fact, the conflict between the two selection processes permitted a Lamarckian soma-to-germline feedback loop. This new element in metazoan ontogeny became the evolvability of the vertebrate adaptive immune system and life as we know it now. We offer the hypothesis that metazoan evolution solved this ancient conflict by evolving an immunogenetic mechanism that responds with rapid Lamarckian efficiency by retaining the ancient reverse transcriptase enzyme (RNACopyright DNA copying discovered by Temin in 1959 (see Temin, 1989) and found in 1970 in RNA tumor viruses by Temin and Baltimore), which can produce cDNA from the genome of an RNA virus that infects the cells. It seems that molecular Lamarckism can survive (Lewin, 1993).
Sujet(s)
Évolution moléculaire , Sélection génétique , Vertébrés/génétique , Allergie et immunologie/histoire , Animaux , Lymphocytes B/immunologie , Lignage cellulaire , ADN/biosynthèse , Réarrangement des gènes des lymphocytes B , Gènes d'immunoglobuline , Génétique/histoire , Centre germinatif/immunologie , Histoire du 19ème siècle , Histoire du 20ème siècle , Modèles génétiques , Modèles immunologiques , Mutation , ARN/génétique , Hypermutation somatique des gènes des immunoglobulines , Vertébrés/embryologie , Vertébrés/immunologieRÉSUMÉ
Previously cloned recombinant A116 single chain fragment variable (scFv) antibody gene has been re-engineered for enhanced reactivity to Venezuelan equine encephalitis virus (VEE) successfully. A PCR-based site-directed mutagenesis approach was adopted to re-introduce the three single-base deletions in the 5' region of the V(L) gene of A116, corresponding to the framework-1 region. The mutagenized A116 was designated as MA116. The introduction of these three bases corrected a localized frame-shift to a consensus framework-1 amino acid sequence. Four MA116 clones (MA116-4, MA116-14, MA116-15, and MA116-16) have been analysed in detail for their reactivity to VEE antigen, and all showed varying degrees of reactivity to VEE antigen. ScFv antibody expressed by MA116-14, MA116-15, and MA116-16 clones showed three to five-fold enhanced enzyme-linked immunosorbant assay reactivity to VEE antigen over the parental A116 clone, while scFv antibody from MA116-4 was less reactive than A116 clone. MA116-15 purified scFv protein showed comparable reactivity to the parental 1A4A-1 monoclonal antibody in recognizing VEE antigen. Sequence analysis revealed that only MA116-15 had incorporated the three intended base insertions. The varying degrees of reactivity of MA116 clones are discussed in light of their molecular changes.
Sujet(s)
Anticorps antiviraux/génétique , Anticorps antiviraux/immunologie , Virus de l'encéphalite équine du Venezuela/immunologie , Fragments d'immunoglobuline/génétique , Région variable d'immunoglobuline/génétique , Séquence d'acides aminés , Animaux , Anticorps monoclonaux/génétique , Anticorps monoclonaux/immunologie , Clonage moléculaire , Gènes d'immunoglobuline , Génie génétique/méthodes , Fragments d'immunoglobuline/immunologie , Région variable d'immunoglobuline/immunologie , Données de séquences moléculaires , Mutagenèse dirigée , Analyse de séquence d'ADNRÉSUMÉ
The evolvability of vertebrate systems involves various mechanisms that eventually generate cooperative and nonlethal functional variation on which Darwinian selection can operate. It is a truism that to get vertebrate animals to develop a coherent machine they first had to inherit the right multicellular ontogeny. The ontogeny of a metazoan involves cell lineages that progressively deny their own capacity for increase and for totipotency in benefit of the collective interest of the individual. To achieve such cell altruism Darwinian dynamics rescinded its original unicellular mandate to reproduce. The distinction between heritability at the level of the cell lineage and at the level of the individual is crucial. However, its implications have seldom been explored in depth. While all out reproduction is the Darwinian measure of success among unicellular organisms, a high replication rate of cell lineages within the organism may be deleterious to the individual as a functional unit. If a harmoniously functioning unit is to evolve, mechanisms must have evolved whereby variants that increase their own replication rate by failing to accept their own somatic duties are controlled. For questions involving organelle origins, see Godelle and Reboud, 1995 and Hoekstra, 1990. In other words, modifiers of conflict that control cell lineages with conflicting genes and new mutant replication rates that deviate from their somatic duties had to evolve. Our thesis is that selection at the level of the (multicellular) individual must have opposed selection at the level of the cell lineage. The metazoan embryo is not immune to this conflict especially with the evolution of set-aside cells and other modes of self-policing modifiers (Blackstone and Ellison, 1998; Ransick et al., 1996. In fact, the conflict between the two selection processes permitted a Lamarckian soma-to-germline feedback loop. This new element in metazoan ontogeny became the evolvability of the vertebrate adaptive immune system and life as we know it now. We offer the hypothesis that metazoan evolution solved this ancient conflict by evolving an immunogenetic mechanism that responds with rapid Lamarckian efficiency by retaining the ancient reverse transcriptase enzyme (RNACopyright DNA copying discovered by Temin in 1959 (see Temin, 1989) and found in 1970 in RNA tumor viruses by Temin and Baltimore), which can produce cDNA from the genome of an RNA virus that infects the cells. It seems that molecular
Sujet(s)
Animaux , Évolution moléculaire , Sélection génétique , Vertébrés/génétique , Allergie et immunologie/histoire , Lignage cellulaire , Centre germinatif/immunologie , ADN , Gènes d'immunoglobuline , Génétique/histoire , Histoire du 19ème siècle , Histoire du 20ème siècle , Lymphocytes B/immunologie , Modèles génétiques , Modèles immunologiques , Mutation , ARN , Réarrangement des gènes des lymphocytes B , Hypermutation somatique des gènes des immunoglobulines , Vertébrés/embryologie , Vertébrés/immunologieRÉSUMÉ
The variable genes of monoclonal antibody (mAb) B10, specific for the C-terminal region of the eukaryotic ribosomal P protein, have been cloned as a single-chain Fv fragment (scFv) and expressed in Escherichia coli. The primary sequence of the variable regions of the B10 antibody, together with a detailed characterization of the reactive residues of the antigen, allowed the construction of a model of the paratope-epitope interaction, giving a first insight into the binding mechanisms of anti-P autoantibodies to their target peptides. The mAb and scFv could be useful for extensive P protein detection since both recognize the highly conserved motif DDxGF.
Sujet(s)
Région variable d'immunoglobuline/génétique , Protéines ribosomiques/immunologie , Motifs d'acides aminés , Séquence d'acides aminés , Animaux , Anticorps monoclonaux/composition chimique , Anticorps monoclonaux/génétique , Sites de fixation des anticorps/génétique , ADN/génétique , Gènes d'immunoglobuline , Région variable d'immunoglobuline/composition chimique , Souris , Modèles moléculaires , Données de séquences moléculaires , Protéines de protozoaire/immunologie , Similitude de séquences d'acides aminés , Trypanosoma cruzi/immunologieSujet(s)
Biochimie , Médecins/histoire , Biologie moléculaire , Prix Nobel , Anticorps monoclonaux , ADN , Gènes d'immunoglobulineSujet(s)
Médecins/histoire , Biochimie , Biologie moléculaire , Prix Nobel , Gènes d'immunoglobuline , ADN , Anticorps monoclonauxRÉSUMÉ
We describe the construction of a phage antibody fragments library which combines, in a single cloning step, a synthetic human light chain variable region (V(L)) with a diverse set of heavy chain variable regions, from a mouse immunized with the prostate specific antigen (PSA). Despite V(L) restriction, selection from this library rendered two different single chain Fv antibody fragments, specifically recognizing PSA. The human V(L), used as a general partner for mouse heavy chains, was constructed by linking the germline A27 gene and the J(K)1 minigene segment, both of which are prominently involved in human antibody responses. Our approach offers a fast and simple way to produce half-human molecules, while keeping the advantage of immunizing animals for high affinity antibodies.
Sujet(s)
Chaines lourdes des immunoglobulines/génétique , Chaines légères des immunoglobulines/génétique , Région variable d'immunoglobuline/génétique , Banque de peptides , Antigène spécifique de la prostate/immunologie , Séquence d'acides aminés , Animaux , Spécificité des anticorps , Séquence nucléotidique , Clonage moléculaire , Escherichia coli/génétique , Gènes d'immunoglobuline , Humains , Chaines lourdes des immunoglobulines/immunologie , Chaines légères des immunoglobulines/immunologie , Région variable d'immunoglobuline/immunologie , Souris , Souris de lignée BALB C , Données de séquences moléculaires , Protéines de fusion recombinantes/immunologie , Alignement de séquences , Analyse de séquence d'ADNRÉSUMÉ
Although a high level of IgE is produced after primary infection with Nippostrongylus brasiliensis (Nb), most of the IgE antibodies (Abs) are not specific to the worm. Analyses with Western blotting and enzyme-linked immunosorbent assay (ELISA) revealed that the IgE Abs from Nb-infected BALB/c mice did not show reactivity with Nb-derived excretory-secretory proteins (NES) and antigens present in the cell-free extracts of the worm. Monoclonal IgE Abs obtained from the Nb-infected mice were not reactive with these Nb antigen either. To characterize Nb-induced IgE response, we used (QM x C57BL/6)F1 (QBF1) mice that bear the knock-in 17.2.25 VHDJH segment (VHT) encoding a VH region specific to 4-hydroxy-3-nitrophenylacetyl hapten, and express VHT-encoded antigen receptors on 80-85% of their B cells. Consistent with the frequency of VHT-positive B cells, more than 80% of IgE Abs induced in QBF1 B cells that were cultured with LPS plus IL-4 were found to bear VHT-encoded H chains. In contrast, when QBF1 mice were infected with Nb, less than 10% of Nb-induced IgE Abs were found to use VHT. The QBF1-derived IgE did not react with Nb antigens either. Taken together, data suggest that Nb-induced IgE response in mice is not merely the result of polyclonal activation of B cells, but may involve a mechanism that revises Ig genes secondarily.
Sujet(s)
Gènes d'immunoglobuline , Immunoglobuline E/génétique , Immunoglobuline E/immunologie , Nippostrongylus/immunologie , Infections à Strongylida/immunologie , Animaux , Anticorps monoclonaux/immunologie , Spécificité des anticorps , Antigènes d'helminthe/immunologie , Réarrangement des gènes des chaines lourdes des lymphocytes B , Commutation de classe des immunoglobulines , Chaines lourdes des immunoglobulines/génétique , Région variable d'immunoglobuline/génétique , Mâle , Souris , Souris de lignée BALB C , Souris de lignée C57BL , Récepteurs pour l'antigène des lymphocytes B/génétique , Récepteurs pour l'antigène des lymphocytes B/immunologie , Recombinaison génétiqueRÉSUMÉ
DNA immunization or inoculation is a recent vaccination method that induces both humoral and cellular immune responses in a range of hosts. Independent of the route or site of vaccination, the transfer of antigen-presenting cells (APC) or antigens into lymphoid organs is necessary. The aim of this investigation was to test whether intraspleen (i.s.) DNA inoculation is capable of inducing a protective immune response. We immunized mice by a single i.s. injection of a DNA construct expressing the immunoglobulin (Ig) heavy-chain variable domain (VH) in which the complementarity-determining regions (CDR) had been replaced by a Taenia crassiceps T-cell epitope. In these mice, immune responses and protective effects elicited by the vaccine were measured. We have shown here for the first time that i.s. DNA inoculation can induce protective cellular immune responses and activate CD8(+) T cells. Also, Ig V(H) appeared to be the minimal delivery unit of "antigenized" Ig capable of inducing T-cell activation in a lymphoid organ. The strategy of introducing T-cell epitopes into the molecular context of the V(H) domain in combination with i.s. DNA immunization could have important implications and applications for human immunotherapy.